Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3298176
14C Tirzepatide · 1 trial · 1 indication
Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.
Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.
| Arm | Type | Description |
|---|---|---|
| 14C Tirzepatide | EXPERIMENTAL | A single dose of \[14C\]-tirzepatide administered subcutaneously (SC). |
| Name | Type | Description |
|---|---|---|
| 14C Tirzepatide | DRUG | Administered SC. |
Inclusion Criteria: * Overtly healthy males as determined by medical history, physical examination, and other screening procedures * Have a body mass index (BMI) between 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive at screening * Are willing to be available for the full duration of t...
14C Tirzepatide is a carbon-14 labeled version of tirzepatide, a small molecule therapeutic developed by Eli Lilly and Company. It is used in clinical research to study the absorption, distribution, metabolism, and excretion of tirzepatide in the body. The drug is in Phase 1 development.
14C Tirzepatide is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Eli Lilly is the sole developer listed for this asset.
14C Tirzepatide is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed.
14C Tirzepatide has been studied in one completed Phase 1 trial, NCT04311424, titled "Study of Tirzepatide in Healthy Participants." The trial enrolled 6 healthy male participants aged 30 years and older in the United Kingdom. It was an uncontrolled study without randomization or double-blinding.
14C Tirzepatide is used as a research tool in clinical trials to investigate the pharmacokinetics of tirzepatide, including its metabolism and excretion. The specific therapeutic indications for this labeled version are undisclosed. The completed Phase 1 trial was conducted in healthy participants.